Oxford vacine is one to play an importante role in Brazil, one of the countries that participated in the testing. First interim analysis, published today in the Lancet, suggests efficacy (70%) but interim data still imprecise (95% CI = 55% - 81%). thelancet.com/journals/lance…
I would not stress the 90% efficacy in those who (by mistake) received a first lower dose. It is a post hoc subgroup analysis of an interim analysis.
I have to confess I had difficult in reading the article. Found confusing. It is not a single clinical trial, it is a pool of different trials, with somewhat different methodologies. Definition of trials to be pooled was not a priori.
Single-blinded, not intention to treat.
Focusing on the half full glass, it is good news in the sense that vacine seems to work. But it should be considered preliminary information. And we need a final publication full of clarity and objectivity. Preferably, stick with predefined analysis.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
